Organon & Co. Common Stock vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Organon & Co. Common Stock trades at $13.77 (market cap $3.61B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.63 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 20.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 92 Days on average.
| OGN | VTIP | |
|---|---|---|
Market Cap | $3.61B | $73.20B |
Volume | 1,808,049 | 3,980,495 |
Sector | Health | — |
52-Week High | $13.81 | $50.46 |
52-Week Low | $5.70 | $48.38 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
VTIP trades at $48.62 with a slight 0.33% daily gain, though technical indicators signal a bearish trend with moving averages and ADX pointing downward. The ETF focuses on short-term inflation-protected securities, offering protection against rising prices while minimizing interest rate sensitivity. Recent institutional buying by firms like NewEdge Advisors and 55 North Private Wealth indicates professional interest in inflation hedging strategies.
The outlook remains cautious given the bearish technical setup, though VTIP's inflation protection role provides defensive appeal amid persistent inflation. Key risks include interest rate volatility and inflation trajectory uncertainty, while the neutral analyst sentiment reflects balanced views on short-term TIPS allocation in current market conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →